Venture Capital

Updated:

Norgine Ventures

Norgine Ventures was established in 2012 as a subsidiary of Norgine, a private European healthcare company founded over 100 years ago. Norgine Ventures...

Norgine Ventures logo

Norgine Ventures

Norgine Ventures was established in 2012 as a subsidiary of Norgine, a private European healthcare company founded over 100 years ago. Norgine Ventures provides debt financing to healthcare and life sciences companies in Europe and the US. The firm has invested in various businesses, including specialty pharma, diagnostic, and medical device companies at different stages of their development.

General information

Firm type

Venture Capital

Year founded

2012

Location

Region

Europe

Country

United Kingdom

City

Uxbridge

Corporate office

Uxbridge, United Kingdom

Sector focus

Healthcare ServicesDigital HealthPharmaceuticals

Frequently asked questions

How does Norgine Ventures finance its investments?

The firm invests directly from Norgine's corporate balance sheet, allowing it to provide growth-stage venture debt alongside minority equity stakes. This structure means it does not raise external funds or operate under fixed fund-life constraints, giving portfolio companies a capital partner that can hold positions indefinitely.

Does Norgine Ventures lead investment rounds or co-invest alongside other firms?

Norgine Ventures commonly provides venture debt as a complement to equity rounds led by traditional venture capital firms. This hybrid approach gives companies non-dilutive growth capital while Norgine takes minority equity exposure, allowing founders and existing investors to retain control.

What is the typical investment size and geographic focus?

The firm writes checks generally ranging from €5 million to €20 million, concentrating on companies headquartered in Western Europe. It has also evaluated opportunities in Israel and the Nordic region, reflecting the broader European footprint of its parent company's commercial operations.

Profile maintained by using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.

Need institutional-grade insight on venture capital firms?

Altss delivers:

Principals with verified direct contactsAllocation history by asset classOSINT-derived deal signals
Book a demo

Prefer a guided tour?

We’ll walk you through:

Interactive funding timelinesCustom mandate & allocation filters
Book a demo

Browse by category

More Uxbridge Venture Capital profiles